News

Learn more about how cognitive behavior therapy can be used as a healing tool in marginalized communities.

Nothing prevents psychiatrists from taking full part in the political process or even the culture wars—as long as they do it outside of their roles as psychiatrists, says one doctor.

“If I am not for myself, who will be? If I am only for myself, what am I? If not now, when?”

Novel treatment for cocaine use disorder? Researchers performed a randomized, double-blind, placebo-controlled trial of lorcaserin.

Do you want to be featured in our online series and potentially in print for an upcoming Special Report? Check out our October theme!

Clinicians can ensure high-quality care by remaining informed about legal and ethical considerations in navigating patient privacy dilemmas.

Any efforts to build lasting peace cannot ignore the massive mental health needs in war-torn regions.

Jelena Kunovac, MD, MS, discusses last week's approval of Cobenfy, an agent with a novel mechanism of action that could revolutionize schizophrenia treatment.

Procrastination: how to conceptualize it for both creative patients and their clinicians.

Dr Miller continues her Ketamine Journal with a mini-group of 2 patients and a cofacilitator.

Goes to the market Just to hear another voice: “Paper or plastic?”

Some studies indicate that individuals who engage in the arts, such as going to the theatre or museums, have a lower risk of dying early.

After 30+ years of clinical experience with clozapine, it is time for professional psychiatry to demand an end to this discriminatory clozapine REMS program.

What is the reality of patient resilience?

How can we enhance our connection to the world and each other?

The vice president of Clinical Development and Medical Affairs, Mental Health at Boehringer Ingelheim shares why it is such an unprecedented moment for schizophrenia research.

Eating pros vs those with eating disorders: what’s the difference?

Cobenfy: Only the first in a new upcoming class of antipsychotics.

While there is still a lot to learn about Cobenfy, here's why it marks a historic moment in the treatment of schizophrenia.

A traumatic brain injury sustained earlier in adult life is likely to interact with normal aging processes. Learn more here.

What can we learn from artists’ memoirs?

Multiple sites are now enrolling participants in a phase 2 clinical trial to evaluate SPG302, the first synaptic regenerative therapy for schizophrenia.

Where do we draw the line on level of impairment for our presidential candidates?

This celebration of the creativity of the arts comes at a time when the arts have been cut in school education and in psychiatry.

The first-in-class muscarinic agonist Cobenfy, formerly known as KarXT, was just approved by the FDA to treat schizophrenia in adults. Are you ready to discuss it with patients and caregivers?

Does reduced blood monitoring impact the detection of hematological abnormalities in clozapine-treated patients? Researchers performed a chart review study from the COVID-10 pandemic.

"A single gem has throbbed in my chest my whole life, even though, even though this is my second heart..."

How can we protect the mental health of our country?

The US Food and Drug Administration approves Cobenfy (KarXT), the first new agent with a novel mechanism of action for schizophrenia more than 50 years.

Mental health clinicians can help empower patients via tools like diet, including the MIND Diet.